KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer-Reference-Cited by-同舟云学术

KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer

Published:2019-02-16 Issue:3 Volume:110 Page:1012-1020
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Nishio Makoto¹^ORCID,Takahashi Toshiaki²,Yoshioka Hiroshige³,Nakagawa Kazuhiko⁴,Fukuhara Tatsuro⁵,Yamada Kazuhiko⁶,Ichiki Masao⁷,Tanaka Hiroshi⁸,Seto Takashi⁹^ORCID,Sakai Hiroshi¹⁰,Kasahara Kazuo¹¹,Satouchi Miyako¹²,Han Shi Rong¹³,Noguchi Kazuo¹³,Shimamoto Takashi¹³,Kato Terufumi¹⁴

Affiliation:

1. Department of Thoracic Medical Oncology; The Cancer Institute Hospital of Japanese Foundation for Cancer Research; Tokyo Japan

2. Division of Thoracic Oncology; Shizuoka Cancer Center; Suntogun Japan

3. Department of Respiratory Medicine; Kurashiki Central Hospital; Kurashiki Japan

4. Department of Medical Oncology; Faculty of Medicine; Kindai University; Osaka-Sayama Japan

5. Department of Respiratory Medicine; Miyagi Cancer Center; Natori Japan

6. Department of Internal Medicine; Division of Respirology, Neurology, and Rheumatology; Kurume University; Kurume Japan

7. Respiratory Medicine; Kyushu Medical Center; Fukuoka Japan

8. Department of Internal Medicine (Pulmonology); Niigata Cancer Center Hospital; Niigata Japan

9. Department of Thoracic Oncology; National Kyushu Cancer Center; Fukuoka Japan

10. Thoracic Oncology; Saitama Cancer Center; Saitama Japan

11. Respiratory Medicine; Kanazawa University Hospital; Kanazawa Japan

12. Department of Thoracic Oncology; Hyogo Cancer Center; Akashi Japan

13. Oncology Science Unit; MSD K.K.; Tokyo Japan

14. Department of Respiratory Medicine; Kanagawa Cardiovascular and Respiratory Center; Yokohama Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cas.13932/fullpdf

Reference22 articles.

1. Center for Cancer Control and Information Services, National Cancer Center Cancer statistics in Japan - 2015 2016 https://ganjoho.jp/en/professional/statistics/brochure/2015_en.html

2. Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line;Leighl;Curr Oncol,2012

3. Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer;Reck;Immunotherapy,2018

4. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

5. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N Engl J Med,2016

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis;Cancers;2024-01-13

2. Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis;Therapeutic Advances in Medical Oncology;2024-01

3. Deciphering the Role of Immune-Checkpoint Inhibitors in Lung Cancer Treatment;Molecular Biomarkers for Cancer Diagnosis and Therapy;2024

4. Drug-induced interstitial lung disease after chemoimmunotherapy for extensive-stage small cell lung cancer;Heliyon;2023-10

5. Biomarkers for Immune Checkpoint Inhibitor Response in NSCLC: Current Developments and Applicability;International Journal of Molecular Sciences;2023-07-25